Viridian Therapeutics, Inc.\DE (VRDN) Preferred Dividend Payments (2016 - 2017)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Preferred Dividend Payments came in at $5000.0 in Q1 2017, up 141.67% year-on-year from $2069.0 in Q1 2016, and down 58.33% quarter-over-quarter from $12000.0 in Q4 2016.
Viridian Therapeutics, Inc.\DE (VRDN) Preferred Dividend Payments (2016 - 2017) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at $5000.0 for Q1 2017.
- On a quarterly basis, Preferred Dividend Payments rose 141.67% year-over-year to $5000.0 in Q1 2017; TTM through Dec 2017 was $5000.0, a 80.0% decrease from a year earlier, with the FY2017 full-year figure at $5000.0, down 89.8% from the prior year.
- Preferred Dividend Payments retreated to $5000.0 in Q1 2017 per VRDN's latest filing, from $12000.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $13000.0 in Q3 2016 and bottomed at -$12000.0 in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Viridian Therapeutics, Inc.\DE | 631.55 Mn | 631.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 5,000.00 |
| Dec 31, 2016 | 12,000.00 |
| Sep 30, 2016 | 13,000.00 |
| Jun 30, 2016 | 12,000.00 |
| Mar 31, 2016 | -12,000.00 |